EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.（EYPT）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · EYPT · 截至 2025年9月30日
股东结构概览
161
机构持有人数
▲ 12 vs Q2
$995.28M
机构持仓总市值
▲ $346.80M vs Q2
83.84M
总流通股
freeFloat 84.05%
69.90M
13F 申报持股数
▲ 986,938 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
EYPT 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
CORMORANT ASSET MANAGEMENT, LP laboratory analytical instruments | 8.32M | 11.91% | 11.91% | $118.55B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC laboratory analytical instruments | 6.19M | 8.86% | 8.86% | $88.18B | Nov 14, 2025 | ▼ 611.4K |
ADAGE CAPITAL PARTNERS GP, L.L.C. laboratory analytical instruments | 5.56M | 7.95% | 7.95% | $79.17B | Nov 14, 2025 | ▼ 1.24M |
BLACKROCK, INC. laboratory analytical instruments | 4.96M | 7.10% | 7.10% | $70.69B | Nov 12, 2025 | ▼ 395.7K |
FEDERATED HERMES, INC. laboratory analytical instruments | 4.42M | 6.32% | 6.32% | $62.89B | Nov 3, 2025 | ▼ 183.1K |
FRANKLIN RESOURCES INC laboratory analytical instruments | 4.17M | 5.97% | 5.97% | $59.41B | Nov 13, 2025 | ▼ 129.2K |
VANGUARD GROUP INC laboratory analytical instruments | 3.79M | 5.43% | 5.43% | $54.03B | Nov 7, 2025 | ▼ 8.1K |
TCG CROSSOVER MANAGEMENT, LLC laboratory analytical instruments | 3.57M | 5.11% | 5.11% | $50.87B | Nov 17, 2025 | — held |
CITADEL ADVISORS LLC laboratory analytical instruments | 2.14M | 3.05% | 3.05% | $30.41B | Nov 14, 2025 | ▼ 208.8K |
PARADIGM BIOCAPITAL ADVISORS LP laboratory analytical instruments | 2.01M | 2.87% | 2.87% | $28.56B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
18
增持
+3.48M 股6
新建仓
首次建仓21
减持
−4.38M 股0
清仓
完全退出净股数变化（前50家）
899.3K
+3.48M / −4.38M
净新增持仓人
+3
新建 6 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
EYPT 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
2
买入笔数
4
卖出笔数
0.50
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Elston George Chief Financial Officer | May 25, 2026 | Tax Withhold | 3,627 | $12.93 | $46.9K | 91.7K | Form 4 ↗ |
Ribeiro Ramiro Chief Medical Officer | Apr 17, 2026 | Sale | 2,437 | $15.00 | $36.6K | 0 | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 76,766 | $13.11 | $1.01M | 177.4K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 97,500 | $20.40 | $1.99M | 97.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 97,500 | $20.40 | $1.99M | 82.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 52,500 | $13.13 | $689.3K | 52.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 52,500 | $13.13 | $689.3K | 7.8K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 76,766 | $13.11 | $1.01M | 986 | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 16, 2026 | Purchase | 1,500 | $13.15 | $19.7K | 100.7K | Form 4 ↗ |
Elston George Chief Financial Officer | Mar 2, 2026 | Gift | 5,000 | — | — | 87.8K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
EyePoint Pharmaceuticals, Inc.（EYPT）主要由机构投资者持有，机构持股比例约为 83.4%。公司内部人员持股约 15.95%，散户及公众持股约占剩余的 0.68%。
EyePoint Pharmaceuticals, Inc. 最大机构股东为 CORMORANT ASSET MANAGEMENT, LP，截至 September 30, 2025 持有约 8.32 million 股，占总流通股的 11.91%。
目前共有 161 家机构持有 EYPT 股票，合计持仓市值约 $995,284,908，数据来源为最新 SEC 13F 申报。
常见问题
EYPT ownershipEyePoint Pharmaceuticals, Inc.（EYPT）主要由机构投资者持有，机构持股约 83.4%。最大股东为 CORMORANT ASSET MANAGEMENT, LP，持股比例 11.91%。内部人员持股约 15.95%。数据来源 SEC Form 13F，截至 September 30, 2025。